# AYTU BIOPHARMA, INC (AYTU) · Edgar & Edgarette company card

> Aytu Biopharma (AYTU) saw revenue fall 13.3% in FY2026 to $58 million, operating margin -14.4% against a -3.8% median for pharmaceutical preparations, equity 33.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1385818 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/AYTU) · [JSON](https://www.pops4.com/boards/company/AYTU.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $58M |
| Revenue growth, 1 year | -13.3% |
| Revenue growth per year | -12.2% |
| Operating margin | -14.4% (prior year -11.8%) |
| Net margin | -24.8% |
| Operating cash flow | $3M |
| Capital spending | $29,000 |
| Free cash flow | $3M |
| Cash | $26M |
| Long-term debt | $11M |
| Total assets | $105M |
| Total equity | $35M |
| Equity ÷ assets | 33.6% |
| Return on equity | -40.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -10.35 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -3.48 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -14.4% in FY2026; revenue is hard to predict: its 80% range is ±67%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $57.6M (FY2026), total debt $11.0M. Experience: revenue down 13.3% on the year, down 12.2% a year over 4 years; operating margin -14.4%, down from -11.8%. Soundness: equity 33.6% of assets, return on equity -40.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $20.4M and $104.0M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $21.7M to $98.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -14.4% against a -3.8% median; growth -13.3% against 13.7%.

Range logged 2026-10-23, receipt 3348a8d95f3e9018, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 10-Q · filed 2026-11-16 · [filing](https://www.sec.gov/Archives/edgar/data/1385818/000143774926037188/0001437749-26-037188-index.htm)
- 8-K · filed 2026-11-16 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1385818/000143774926037176/0001437749-26-037176-index.htm)
- 8-K · filed 2026-11-16 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1385818/000143774926037155/0001437749-26-037155-index.htm)
- DEF 14A · filed 2026-10-22 · [filing](https://www.sec.gov/Archives/edgar/data/1385818/000143774926033276/0001437749-26-033276-index.htm)
- 10-K · filed 2026-09-22 · [filing](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/0001437749-26-030908-index.htm)
- 8-K · filed 2026-09-22 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/0001437749-26-030900-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001385818.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1385818

## Cite

POPS4, Edgar & Edgarette: AYTU BIOPHARMA, INC (AYTU) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/AYTU. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

